Skip to main content
Clinical Trials/NCT04064008
NCT04064008Enrolling By InvitationNot Applicable

Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Z Revision Femoral Stems

MicroPort Orthopedics Inc.1 site in 1 country30 target enrollmentStarted: April 4, 2019Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Enrolling By Invitation
Enrollment
30
Locations
1
Primary Endpoint
Survivorship of ProFemur Z Stem out to 10 years

Study Overview

Brief Summary

Single center, prospective follow-up of previously implanted subjects

Detailed Description

Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Z Revision Femoral Stems

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Retrospective

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Has undergone a revision for nonunion and/or hardware removal (i.e. all conditions resulting in poor quality proximal bone).
  • Subject is implanted with the PROFEMUR® Z Revision Femoral Stem at the time of their revision THA.
  • Subject is willing and able to complete required study visits or assessments.
  • Plans to be available through the 10 year postoperative follow-up visit.
  • Previously implanted bilateral subjects can have both THAs enrolled in the study provided:
  • the PROFEMUR Z Revision Femoral Stem was implanted in both,
  • all other aspects of the Inclusion/Exclusion Criteria are satisfied,
  • enrollment does not exceed the subject count specified in the Clinical Trial Agreement, and
  • the subject agrees to a second Informed Consent document specific to the second THA. Prospective enrollment of a previously unimplanted hip is not permitted in this study.

Exclusion Criteria

  • Subjects currently enrolled in another clinical study which could affect the endpoints of this protocol.
  • Subject has a PROFEMUR Neck Varus/Valgus CoCr 8 Degree, Part number PHAC 1254 implanted in the enrolled THA.
  • Has or had an overt infection at the time of implantation.
  • Has or had a distant foci of infections (which may cause hematogenous spread to the implant site) at the time of implantation.
  • Has or had a rapid disease progression as manifested by joint destruction or bone absorption apparent on roentgenogram at the time of implantation.
  • Has or had inadequate neuromuscular status (e.g., prior paralysis, fusion, and/or inadequate abductor strength), poor bone stock, poor skin coverage around the joint which would make the procedure unjustifiable.
  • Subjects unwilling to sign the Informed Consent document.
  • Subjects with substance abuse issues.
  • Subjects with an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study.
  • Subjects who are incarcerated or have pending incarceration.

Outcomes

Primary Outcomes

Survivorship of ProFemur Z Stem out to 10 years

Time Frame: 10 years.

Kaplan-Meier survivorship at specific intervals out to 10 years follow up

Secondary Outcomes

  • to characterize total functional scores for subjects, as assessed by Oxford Hip Scores(2-5 years, 5-7 years, and 10 years.)
  • Revision rate of the Profemur Z stem out to 10 years(2-5 years, 5-7 years, and 10 years.)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials